Harrison Department of Surgical Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Curr Opin Immunol. 2011 Oct;23(5):685-91. doi: 10.1016/j.coi.2011.07.011.
T lymphocytes are the primary targets of immunotherapy in clinical transplantation. However, B lymphocytes are detrimental to graft survival by virtue of their capacity to present antigen to T cells via the indirect pathway of allorecognition and the generation of donor specific alloantibody. Furthermore, the long-term survival of organ allografts remains challenged by chronic rejection, a process in which activated B cells have been found to play a significant role. Therefore, the achievement of transplantation tolerance will likely require induction of both T and B cell tolerance to alloantigens. Moreover, human and animal investigations have shown that subsets of B cells, Transitional and Regulatory, are inherently tolerogenic. Developing therapeutic strategies that exploit these populations may be key to achieving transplantation tolerance. In this review we describe the current evidence for the essential role of B cells in transplant tolerance and discuss emerging B cell directed strategies to achieve allograft tolerance.
T 淋巴细胞是临床移植中免疫治疗的主要靶点。然而,B 淋巴细胞通过间接途径的同种识别和产生供体特异性同种抗体向 T 细胞呈递抗原,从而对移植物存活产生不利影响。此外,器官同种移植物的长期存活仍然受到慢性排斥的挑战,在这个过程中,已发现激活的 B 细胞起着重要作用。因此,实现移植耐受可能需要诱导对同种抗原的 T 细胞和 B 细胞耐受。此外,人体和动物研究表明,B 细胞的亚群,过渡性和调节性,天生具有免疫耐受性。开发利用这些群体的治疗策略可能是实现移植耐受的关键。在这篇综述中,我们描述了 B 细胞在移植耐受中的重要作用的现有证据,并讨论了实现同种异体移植耐受的新兴 B 细胞靶向策略。